Compounds > cryptolepine monohydrochloride
Page last updated: 2024-12-08

cryptolepine monohydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID156093
CHEMBL ID92129
SCHEMBL ID5803104
MeSH IDM0315537

Synonyms (10)

Synonym
5h-quindoline, 5-methyl-, monohydrochloride
5-methyl-5h-quindoline hydrochloride
CHEMBL92129
cryptolepine hcl
cryptolepine hydrochloride
nsc-647765
72782-09-3
SCHEMBL5803104
DTXSID60223112
5-methyl-5h-indolo[3,2-b]quinoline hydrochloride
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histidine-rich protein PFHRP-IIPlasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)1,720,000.00000.07651.12552.9000AID401645
Cysteine protease Trypanosoma brucei rhodesienseIC50 (µMol)23.00000.00313.87667.7500AID682946
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (171)

Assay IDTitleYearJournalArticle
AID118223Mean body weight measured in genetically altered obese diabetic mice(db/db) at 100 mg/kg at 0 hr postdose1998Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15
Antihyperglycemic activities of cryptolepine analogues: an ethnobotanical lead structure isolated from Cryptolepis sanguinolenta.
AID533305Downregulation of FTR1 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID453256Antileishmanial activity against Leishmania donovani axenic amastigotes2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID570298Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for chloroquine-resistant ring stage Plasmodium falciparum W22011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.
AID113571Food intake in C57BL/ks Mice expressed as gram/mouse/day and the observation made at 0 -24 Hrs, when administered at a dose of 30 mg/kg1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID744360Inhibition of IL1beta-induced p38 MAPK phosphorylation in human SK-N-SH cells at 10 to 20 uM preincubated for 30 mins prior to IL1beta-stimulation measured after 1 hr by Western blotting analysis2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID533046Upregulation of TPS1 gene expression in Saccharomyces cerevisiae at 7.5 uM after 15 hrs by qRT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID533039Downregulation of PHO5 gene expression in Saccharomyces cerevisiae at 7.5 uM after 15 hrs by microarray analysis relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID533041Downregulation of TIS11 gene expression in Saccharomyces cerevisiae at 7.5 uM after 15 hrs by microarray analysis relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID402125Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes by [3H]hypoxanthine uptake1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID533304Upregulation of FET5 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID570300Antiplasmodial activity against GFP-expressing liver stage Plasmodium berghei sporozoites infected in human Huh-7 cells at 5 uM by fluorescence activated cell sorting based method2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.
AID533034Cytotoxicity against Saccharomyces cerevisiae2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID314181Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W22008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Cryptolepine analogues containing basic aminoalkyl side-chains at C-11: synthesis, antiplasmodial activity, and cytotoxicity.
AID682945Inhibition of Trypanosoma brucei CatB2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Antitrypanosomal and cysteine protease inhibitory activities of alkyldiamine cryptolepine derivatives.
AID744371Cytotoxicity against human SK-N-SH cells after 24 hrs by ATP assay2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID570299Resistance index, ratio of IC50 for chloroquine-resistant ring stage Plasmodium falciparum W2 to IC50 for chloroquine-sensitive ring stage Plasmodium falciparum 3D72011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.
AID533308Downregulation of SMF1 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID533043Upregulation of HSP26 gene expression in Saccharomyces cerevisiae at 7.5 uM after 15 hrs by microarray analysis relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID3425In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.1998Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15
Antihyperglycemic activities of cryptolepine analogues: an ethnobotanical lead structure isolated from Cryptolepis sanguinolenta.
AID118216Compound was evaluated for the in vivo effects on plasma glucose concentrations in db/db mice administered at a dose of 30 mg/kg mean body weight expressed as grams/mouse at 0 hr1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID744369Inhibition of COX2 protein expression in IL1beta-stimulated human SK-N-SH cells at 5 to 20 uM after 24 hrs by Western blotting analysis2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID533055Upregulation of HSP26 gene expression in Saccharomyces cerevisiae at 17 uM after 15 hrs by microarray analysis relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID380511Growth inhibition of Saccharomyces cerevisiae 1353 mutant by yeast bioassay1999Journal of natural products, Jul, Volume: 62, Issue:7
Synthesis and biological evaluation of analogues of cryptolepine, an alkaloid isolated from the Suriname rainforest.
AID171166In vitro effect of drug administration on Body weight in Fructose fed STZ-treated rats, after 24 hr (Treatment group - Fructose/STZ )1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID402126Antiplasmodial activity against Plasmodium falciparum K1 infected human erythrocytes by [3H]hypoxanthine uptake1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID1466364Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 after 24 hrs by liquid scintillation counting analysis2017European journal of medicinal chemistry, Jul-07, Volume: 134Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view.
AID570301Drug uptake in Plasmodium falciparum infected in human erythrocyte nucleus at 5 uM after 3 hrs by fluorescence microscopy2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.
AID252244In vivo antimalarial activity of compound against Plasmodium berghei in mice (Mus musculus) at dose of 20 mg/kg treated for 4 days; c = toxic after 2nd dose2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID533048Downregulation of ARN2 gene expression in Saccharomyces cerevisiae at 17 uM after 15 hrs by qRT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID124206Effect when given at 30 mg/kg in (C57BL/ks) mouse,Predose1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID171170In vitro effect of drug administration on Body weight in Fructose fed STZ-treated rats, pre dose (Treatment group - Fructose/STZ )1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID570295Antiplasmodial activity against chloroquine and pyrimethamine-resistant ring stage Plasmodium falciparum V1/S infected in human red blood cells after 48 hrs2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.
AID118215Compound was evaluated for the in vivo effects on plasma glucose concentrations in db/db mice administered at a dose of 20 mg/kg mean body weight expressed as grams/mouse at 24 hr1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID533302Downregulation of FRE6 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID533300Upregulation of FRE2 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID533047Downregulation of ARN2 gene expression in Saccharomyces cerevisiae at 17 uM after 15 hrs by microarray analysis relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID570302Drug uptake in Plasmodium falciparum infected in human erythrocyte food vacuoles at 5 uM after 3 hrs by fluorescence microscopy2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.
AID533303Downregulation of FET3 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID171169In vitro effect of drug administration on Body weight in Fructose fed STZ-treated rats, pre dose (Treatment group - Chow)1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID533038Downregulation of FIT3 gene expression in Saccharomyces cerevisiae at 7.5 uM after 15 hrs by qRT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID533058Upregulation of TPS1 gene expression in Saccharomyces cerevisiae at 17 uM after 15 hrs by qRT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID533309Upregulation of SMF2 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID300739Activity of recombinant human NQO1 assessed as specific activity2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Synthesis of cryptolepine analogues as potential bioreducible anticancer agents.
AID113579Food intake measured in genetically altered obese diabetic mice(db/db) at 100 mg/kg dose1998Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15
Antihyperglycemic activities of cryptolepine analogues: an ethnobotanical lead structure isolated from Cryptolepis sanguinolenta.
AID171034In vitro effect of drug administration on Body weight in Fructose fed STZ-treated rats, after 24 hr (Treatment group - Chow)1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID179031In vitro effect of drug administration on food consumption in Fructose fed STZ-treated rats (Treatment group - Fructose/STZ + cryptoline HCl, 30 mg/kg)1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID533056Upregulation of HSP26 gene expression in Saccharomyces cerevisiae at 17 uM after 15 hrs by qRT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID453258Toxicity against rat L6 cells2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID113572Food intake in C57BL/ks Mice expressed as gram/mouse/day and the observation made at 24-48 Hrs, when administered at a dose of 30 mg/kg1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID533050Downregulation of FIT3 gene expression in Saccharomyces cerevisiae at 17 uM after 15 hrs by qRT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID744362Inhibition of IL1beta-induced NFkappaB p65 nuclear translocation in human SK-N-SH cells after 15 mins by ELISA2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID402128Antimalarial activity as reduced parasitaemia against Plasmodium berghei infected Swiss albino mice (Mus musculus) at 50 mg/kg/day peroral dose for 4 days1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID380512Cytotoxicity against mouse M109 cells1999Journal of natural products, Jul, Volume: 62, Issue:7
Synthesis and biological evaluation of analogues of cryptolepine, an alkaloid isolated from the Suriname rainforest.
AID249426Ratio of cytotoxic to that of antiplasmodial activity was determined2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID253253In vivo antimalarial activity of compound against Plasmodium berghei was determined as suppression of parasitaemia in mice (Mus musculus) at 20 mg/kg treated for 4 days; c=toxic after the 2nd dose2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID533310Downregulation of SMF3 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID682943Antitrypanosomal activity against Trypanosoma brucei brucei2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Antitrypanosomal and cysteine protease inhibitory activities of alkyldiamine cryptolepine derivatives.
AID533307Downregulation of FET4 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID453254Antitrypanosomal activity against Trypanosoma brucei rhodesiense2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID118214Compound was evaluated for the in vivo effects on plasma glucose concentrations in db/db mice administered at a dose of 20 mg/kg mean body weight expressed as grams/mouse at 0 hr1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID533049Downregulation of FIT3 gene expression in Saccharomyces cerevisiae at 17 uM after 15 hrs by microarray analysis relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID118219Mean body weight expressed as grams/mouse at 24hrs, when given at 100 mg/kg1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID402127Antimalarial activity as reduced parasitaemia against Plasmodium berghei yoelii infected Swiss albino mice (Mus musculus) at 50 mg/kg/day peroral dose for 4 days1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID380509Growth inhibition of Saccharomyces cerevisiae 1138 mutant by yeast bioassay1999Journal of natural products, Jul, Volume: 62, Issue:7
Synthesis and biological evaluation of analogues of cryptolepine, an alkaloid isolated from the Suriname rainforest.
AID179029In vitro effect of drug administration on food consumption in Fructose fed STZ-treated rats (Treatment group - Chow)1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID118222Mean body weight expressed as grams/mouse (C57BL/ks) at 48hrs, when given at 30 mg/kg1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID110751Change in plasma glucose levels measured in genetically altered obese diabetic mice(db/db) at 100 mg/kg at 24 hr postdose1998Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15
Antihyperglycemic activities of cryptolepine analogues: an ethnobotanical lead structure isolated from Cryptolepis sanguinolenta.
AID744365Inhibition of microsomal PGES-1 gene expression in IL1beta-stimulated human SK-N-SH cells at 2.5 uM preincubated for 30 mins prior to IL1beta-stimulation measured after 4 hrs by qPCR analysis2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID253014Mean survival time taken as number of days before illness due to Plasmodium berghei when mice (Mus musculus) treated with 20 mg/kg dose for 4 days; c=toxic after the 2nd dose2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID3389In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID533298Downregulation of FIT3 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID570308Inhibition of Plasmodium falciparum falcipain 22011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.
AID533044Upregulation of HSP26 gene expression in Saccharomyces cerevisiae at 7.5 uM after 15 hrs by qRT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID744364Inhibition of microsomal PGES-1 gene expression in IL1beta-stimulated human SK-N-SH cells at 5 uM preincubated for 30 mins prior to IL1beta-stimulation measured after 4 hrs by qPCR analysis2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID460284Selectivity ratio of IC50 for rat L6 cells to IC50 for Plasmodium falciparum K12010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Antimalarial and antitubercular nostocarboline and eudistomin derivatives: synthesis, in vitro and in vivo biological evaluation.
AID3426In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.1998Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15
Antihyperglycemic activities of cryptolepine analogues: an ethnobotanical lead structure isolated from Cryptolepis sanguinolenta.
AID744375Inhibition of microsomal PGES-1 protein expression in IL1beta-stimulated human SK-N-SH cells at 10 to 20 uM after 24 hrs by Western blotting analysis2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID460277Antiparasitic activity against Plasmodium falciparum K12010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Antimalarial and antitubercular nostocarboline and eudistomin derivatives: synthesis, in vitro and in vivo biological evaluation.
AID533297Downregulation of FIT2 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID744372Antiinflammatory activity against human SK-N-SH cells assessed as inhibition of IL1beta-induced IL6 production at 2.5 to 20 uM preincubated for 30 mins prior to IL1beta-stimulation measured after 24 hrs by ELISA2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID744366Inhibition of microsomal PGES-1 protein expression in IL1beta-stimulated human SK-N-SH cells at 5 uM after 24 hrs by Western blotting analysis2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID179030In vitro effect of drug administration on food consumption in Fructose fed STZ-treated rats (Treatment group - Fructose/STZ )1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID744370Inhibition of COX2 protein expression in IL1beta-stimulated human SK-N-SH cells at 2.5 uM after 24 hrs by Western blotting analysis relative to IL1beta-treated control2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID401637Antitrypanosomal activity against Trypanosoma brucei rhodesiense2005Journal of natural products, May, Volume: 68, Issue:5
Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.
AID533042Downregulation of TIS11 gene expression in Saccharomyces cerevisiae at 7.5 uM after 15 hrs by qRT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID570309Inhibition of Plasmodium falciparum falcipain 32011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.
AID253007Mean survival time taken as number of days before illness due to Plasmodium berghei in untreated mice (Mus musculus); c=toxic after the 2nd dose2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID3427In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.1998Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15
Antihyperglycemic activities of cryptolepine analogues: an ethnobotanical lead structure isolated from Cryptolepis sanguinolenta.
AID570293Antiplasmodial activity against chloroquine-resistant ring stage Plasmodium falciparum W2 infected in human red blood cells after 48 hrs2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.
AID300737Cytotoxicity against high NQO1 protein expressing human H460 cells by MTT assay2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Synthesis of cryptolepine analogues as potential bioreducible anticancer agents.
AID402124Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes by [3H]hypoxanthine uptake1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID453259Selectivity index, ratio of IC50 for rat L6 cells to IC50 for chloroquine and pyrimethamine-resistant Plasmodium falciparum K12009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID113573Food intake in db/db Mice expressed as gram/mouse/day and the observation made at 0 - 24 Hrs, in db/db mice administered at a dose of 20 mg/kg1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID682944Inhibition of Trypanosoma cruzi cruzaine2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Antitrypanosomal and cysteine protease inhibitory activities of alkyldiamine cryptolepine derivatives.
AID3390In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID744373Antiinflammatory activity against human SK-N-SH cells assessed as inhibition of IL1beta-induced TNFalpha production at 2.5 to 20 uM preincubated for 30 mins prior to IL1beta-stimulation measured after 24 hrs by ELISA2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID401641Cytotoxicity against rat L6 cells2005Journal of natural products, May, Volume: 68, Issue:5
Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.
AID533306Downregulation of FTH1 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID124207Effect when given at 30 mg/kg in (C57BL/ks) mouse, after day 31998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID113574Food intake in db/db Mice expressed as gram/mouse/day and the observation made at 0 - 24 Hrs, in db/db mice administered at a dose of 30 mg/kg1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID118221Mean body weight expressed as grams/mouse (C57BL/ks) at 24hrs, when given at 30 mg/kg1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID113575Food intake in db/db Mice expressed as gram/mouse/day and the observation made at 24 - 48 Hrs, in db/db mice administered at a dose of 20 mg/kg1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID171167In vitro effect of drug administration on Body weight in Fructose fed STZ-treated rats, after 24 hr (Treatment group - Fructose/STZ + cryptoline HCl, 30 mg/kg)1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID533045Upregulation of TPS1 gene expression in Saccharomyces cerevisiae at 7.5 uM after 15 hrs by microarray analysis relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID124208Effect when given at 30 mg/kg in (db/db)mice,3 days postdose1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID118217Compound was evaluated for the in vivo effects on plasma glucose concentrations in db/db mice administered at a dose of 30 mg/kg mean body weight expressed as grams/mouse at 24 hr1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID570297Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.
AID533060Downregulation of glucose catabolic process related gene expression in Saccharomyces cerevisiae2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID300738Cytotoxicity against low NQO1 protein expressing human BE cells by MTT assay2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Synthesis of cryptolepine analogues as potential bioreducible anticancer agents.
AID247907Cytotoxicity against MAC15A mouse adenocarcinomas of the colon cells2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID284197Inhibition of LPS-stimulated nitric oxide production in mouse RAW 264.7 cells at 10 uM after 20 hrs relative to control2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthetic cryptolepine inhibits DNA binding of NF-kappaB.
AID118224Mean body weight measured in genetically altered obese diabetic mice(db/db) at 100 mg/kg at 24 hr postdose1998Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15
Antihyperglycemic activities of cryptolepine analogues: an ethnobotanical lead structure isolated from Cryptolepis sanguinolenta.
AID533036Downregulation of ARN2 gene expression in Saccharomyces cerevisiae at 7.5 uM after 15 hrs by qRT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID96364In vitro cell survival assay on cancer KB cell lines2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
New synthesis of benzo-delta-carbolines, cryptolepines, and their salts: in vitro cytotoxic, antiplasmodial, and antitrypanosomal activities of delta-carbolines, benzo-delta-carbolines, and cryptolepines.
AID118220Mean body weight expressed as grams/mouse (C57BL/ks) at 0hrs, when given at 30 mg/kg1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID453255Antitrypanosomal activity against Trypanosoma cruzi2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID401638Antitrypanosomal activity against Trypanosoma cruzi2005Journal of natural products, May, Volume: 68, Issue:5
Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.
AID533035Downregulation of ARN2 gene expression in Saccharomyces cerevisiae at 7.5 uM after 15 hrs by microarray analysis relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID118218Mean body weight expressed as grams/mouse at 0hrs, when given at 100 mg/kg1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID533032Cytotoxicity against Saccharomyces cerevisiae BY4741 harboring deltaerg6 mutant gene after 4 hrs2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID744367Inhibition of microsomal PGES-1 protein expression in IL1beta-stimulated human SK-N-SH cells at 2.5 uM after 24 hrs by Western blotting analysis2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID284196Inhibition of LPS-stimulated nitric oxide production in mouse RAW 264.7 cells at 5 uM after 20 hrs relative to control2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthetic cryptolepine inhibits DNA binding of NF-kappaB.
AID380510Growth inhibition of Saccharomyces cerevisiae 1140 mutant by yeast bioassay1999Journal of natural products, Jul, Volume: 62, Issue:7
Synthesis and biological evaluation of analogues of cryptolepine, an alkaloid isolated from the Suriname rainforest.
AID570305Binding affinity to s(GATCCTAGGATC)2-DNA by UV-visible spectrophotometry2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.
AID533062Downregulation of fungal type cell wall related gene expression in Saccharomyces cerevisiae2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID533294Downregulation of ARN2 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID314183Ratio of IC50 for human HUVEC cells to IC50 for Plasmodium falciparum W22008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Cryptolepine analogues containing basic aminoalkyl side-chains at C-11: synthesis, antiplasmodial activity, and cytotoxicity.
AID1466363Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 after 24 hrs by liquid scintillation counting analysis2017European journal of medicinal chemistry, Jul-07, Volume: 134Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view.
AID533031Cytotoxicity against Saccharomyces cerevisiae JN394 harboring deltarad52 mutant gene after 4 hrs2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID744374Antiinflammatory activity against human SK-N-SH cells assessed as inhibition of IL1beta-induced PGE2 production preincubated for 30 mins prior to IL1beta-stimulation measured after 24 hrs by enzyme immunoassay2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID682948Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Trypanosoma brucei brucei2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Antitrypanosomal and cysteine protease inhibitory activities of alkyldiamine cryptolepine derivatives.
AID682946Inhibition of Trypanosoma brucei rhodesiense rhodesain2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Antitrypanosomal and cysteine protease inhibitory activities of alkyldiamine cryptolepine derivatives.
AID300735Cytotoxicity against NQO2 expressing human RT112 cells by MTT assay2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Synthesis of cryptolepine analogues as potential bioreducible anticancer agents.
AID300736Cytotoxicity against NQO2 expressing human RT112 cells in presence of NRH cofactor by MTT assay2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Synthesis of cryptolepine analogues as potential bioreducible anticancer agents.
AID113576Food intake in db/db Mice expressed as gram/mouse/day and the observation made at 24 - 48 Hrs, in db/db mice administered at a dose of 30 mg/kg1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID533033Cytotoxicity against Saccharomyces cerevisiae BY4741 harboring deltaerg6 mutant gene at <10 uM after 4 hrs2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID744361Inhibition of IL1beta-induced IkappaB phosphorylation in human SK-N-SH cells at 2.5 to 20 uM after 15 mins by ELISA2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID533059Downregulation of siderophore transport related gene expression in Saccharomyces cerevisiae2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID533299Downregulation of FRE1 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID570294Antiplasmodial activity against chloroquine-sensitive ring stage Plasmodium falciparum 3D7 infected in human red blood cells after 48 hrs2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.
AID247780In vitro antiplasmodial activity for Plasmodium falciparum2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID533040Downregulation of PHO5 gene expression in Saccharomyces cerevisiae at 7.5 uM after 15 hrs by qRT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID533051Downregulation of PHO5 gene expression in Saccharomyces cerevisiae at 17 uM after 15 hrs by microarray analysis relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID533293Downregulation of ARN1 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID453257Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum K1 by [3H]hypoxanthine incorporation assay2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID401640Antiplasmodial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum K1 by [3H]hypoxanthine uptake2005Journal of natural products, May, Volume: 68, Issue:5
Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.
AID314182Cytotoxicity against HUVEC cells2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Cryptolepine analogues containing basic aminoalkyl side-chains at C-11: synthesis, antiplasmodial activity, and cytotoxicity.
AID401639Antileishmanial activity against Leishmania donovani2005Journal of natural products, May, Volume: 68, Issue:5
Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.
AID744359Inhibition of p38 MAPK in human SK-N-SH cells assessed as inhibition of IL1beta-induced MAPKAPK2 phosphorylation preincubated for 30 mins prior to IL1beta-stimulation measured after 1 hr by Western blotting analysis2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID744368Inhibition of COX2 gene expression in IL1beta-stimulated human SK-N-SH cells at 10 to 20 uM preincubated for 30 mins prior to IL1beta-stimulation measured after 4 hrs by qPCR analysis2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID533296Downregulation of FIT1 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID570296Antiplasmodial activity against chloroquine-sensitive, mefloquine-resistant ring stage Plasmodium falciparum D6 infected in human red blood cells after 48 hrs2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.
AID533054Downregulation of TIS11 gene expression in Saccharomyces cerevisiae at 17 uM after 15 hrs by qRT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID570306Binding affinity to heme by UV-visible titration2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.
AID744363Inhibition of microsomal PGES-1 gene expression in IL1beta-stimulated human SK-N-SH cells at 10 to 20 uM preincubated for 30 mins prior to IL1beta-stimulation measured after 4 hrs by qPCR analysis2013European journal of medicinal chemistry, May, Volume: 63Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition.
AID533061Downregulation of acid phosphatase activity related gene expression in Saccharomyces cerevisiae2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID533053Downregulation of TIS11 gene expression in Saccharomyces cerevisiae at 17 uM after 15 hrs by microarray analysis relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID396383Antimalarial activity against chloroquine-resistant Plasmodium falciparum K12008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Pharmacophore based discovery of potential antimalarial agent targeting haem detoxification pathway.
AID401645Inhibition of beta-hematin formation by BHIA assay2005Journal of natural products, May, Volume: 68, Issue:5
Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.
AID533037Downregulation of FIT3 gene expression in Saccharomyces cerevisiae at 7.5 uM after 15 hrs by microarray analysis relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID113578Food intake in db/db Mice expressed as gram/mouse/day and the observed after 48 hr.1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID533057Upregulation of TPS1 gene expression in Saccharomyces cerevisiae at 17 uM after 15 hrs by microarray analysis relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID533052Downregulation of PHO5 gene expression in Saccharomyces cerevisiae at 17 uM after 15 hrs by qRT-PCR relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID401646Displacement of methyl green dye from DNA2005Journal of natural products, May, Volume: 68, Issue:5
Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.
AID171168In vitro effect of drug administration on Body weight in Fructose fed STZ-treated rats, pre dose ((Treatment group - Fructose/STZ + cryptoline HCl, 30 mg/kg)1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID533295Downregulation of SIT1 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID682947Cytotoxicity against african green monkey Vero cells2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Antitrypanosomal and cysteine protease inhibitory activities of alkyldiamine cryptolepine derivatives.
AID110752Change in plasma glucose levels measured in genetically altered obese diabetic mice(db/db) at 100 mg/kg at 3 hr postdose1998Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15
Antihyperglycemic activities of cryptolepine analogues: an ethnobotanical lead structure isolated from Cryptolepis sanguinolenta.
AID533301Downregulation of FRE5 gene expression in Saccharomyces cerevisiae relative to untreated control2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
AID533063Downregulation of stress response related gene expression in Saccharomyces cerevisiae2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (22.22)18.2507
2000's9 (50.00)29.6817
2010's5 (27.78)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.66 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
quinacrine
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.		2.0410acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
diminazene
Diminazene: An effective trypanocidal agent.. diminazene : A triazene derivative that is triazene in which each of the terminal nitrogens is substituted by a 4-carbamimidoylphenyl group.		2.0410carboxamidine;
triazene derivative		antiparasitic agent;
trypanocidal drug
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		3.2860aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
miltefosine
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.		2.4420phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
mefloquine hydrochloride
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.		1.9910organofluorine compound;
piperidines;
quinolines;
secondary alcohol
melarsoprol
Melarsoprol: Arsenical used in trypanosomiases. It may cause fatal encephalopathy and other undesirable side effects.		2.4420triazines
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		2.4420furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
benzonidazole
benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.		2.4420C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		3.2510azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
chloroquine diphosphate
[no description available]		2.0210
propamidine
propamidine: structure given in first source. propamidine : A polyether that is the bis(4-guanidinophenyl) ether of propane-1,3-diol. Used (as its isethionate salt) for the treatment of minor eye or eyelid infections, such as conjunctivitis and blepharitis.		2.0410aromatic ether;
guanidines;
polyether		antimicrobial agent;
antiseptic drug
tebuquine
[no description available]		2.0410
fascaplysine
fascaplysine: from tropic sea sponges		2.0510
cryptolepine
cryptolepine: fused indole-quinoline; structure in first source; from CRYPTOLEPIS sanguinolenta. cryptolepine : An organic heterotetracyclic compound that is 5H-indolo[3,2-b]quinoline in which the hydrogen at position N-5 is replaced by a methyl group.		4.570indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound		anti-inflammatory agent;
antimalarial;
antineoplastic agent;
cysteine protease inhibitor;
plant metabolite
tretazicar
tretazicar: minor descriptor (75-84); on-line & Index Medicus search AZIRIDINES (75-84)		2.0310
tetrahydroharmane
[no description available]		2.0510
canthin-6-one
canthin-6-one: from Zanthoxylum usambarense; structure in first source. canthin-6-one : An indole alkaloid that is 6H-indolo[3,2,1-de][1,5]naphthyridine substituted by an oxo group at position 6.		3.2510enone;
indole alkaloid;
organic heterotetracyclic compound		antimycobacterial drug;
metabolite
quindoline
quindoline: a fused indole-quinoline alkaloid from CRYPTOLEPIS sanguinolenta; structure		2.6930
parthenolide
[no description available]		2.0310germacranolide
n,n-dideethylchloroquine
[no description available]		2.0410
3,6-diamino-9-(4-(methylsulfonyl)aminophenyl)aminoacridine
[no description available]		2.0410
4-methoxy-1-vinylcarboline
[no description available]		2.0510
uleine
uleine: from the bark of Plumeria lancifolia; structure in first source		3.2510
isocryptolepine
isocryptolepine: synthetic antimalarial alkaloid; structure in first source		2.0510
neocryptolepine
neocryptolepine: isolated from the roots of the African plant Cryptolepis sanguinolenta; structure in first source		3.8330
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		2.0410cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
quinine
[no description available]		2.7130cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
harman
harman: a beta-carboline; RN given refers to parent cpd; structure. harman : An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A.		2.0510harmala alkaloid;
indole alkaloid fundamental parent;
indole alkaloid		anti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
stilbamidine
stilbamidine: RN given refers to parent cpd		2.0410
apaziquone
apaziquone: structure given in first source; RN given refers to (E)-isomer		2.0310indoles
laq824
LAQ824: Histone deacetylase inhibitor		3.2510
manzamine a
manzamine A: RN given refers to (1R-(1R*,9Z,13S*,13aR*,20aR*,21aR*)-isomer; RN for cpd without isomeric designation not avail 12/92. manzamine A : An alkaloid of the class of beta-carbolines isolated from Haliclona and Acanthostrongylophora. It exhibits inhibitory activity against Glycogen Synthase Kinase-3 (EC 2.7.11.26).		3.2510alkaloid;
beta-carbolines;
isoquinolines		animal metabolite;
anti-HSV-1 agent;
antimalarial;
antineoplastic agent;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
marine metabolite
pf-562,271
[no description available]		3.2510indoles
indolmycin
indolmycin: produced by a strain of Streptomyces griseus; RN given refers to cpd without isomeric designation; structure. indolmycin : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted at the 2 and 5-pro-S positions by methylamino and [(1R)-1-(1H-indol-3-yl)ethyl] groups, respectively.		3.25101,3-oxazoles;
indoles;
secondary amino compound		antibacterial agent;
antimicrobial agent;
bacterial metabolite;
EC 6.1.1.2 (tryptophan--tRNA ligase) inhibitor
trigonoliimine a
trigonoliimine A: from the leaves of Trigonostemon lii; structure in first source		3.2510
ConditionIndicatedRelationship StrengthStudiesTrials
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9910
Alloxan Diabetes
[description not available]		02.420
Infections, Plasmodium
[description not available]		02.0210
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		02.0210
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		02.0810
Bacterial Disease
[description not available]		03.0610
Abdominal Migraine
[description not available]		03.0610
Fungal Diseases
[description not available]		03.0610
Benign Neoplasms
[description not available]		03.0610
Viral Diseases
[description not available]		03.0610
Bacterial Infections
Infections by bacteria, general or unspecified.		03.0610
Migraine Disorders
A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)		03.0610
Mycoses
Diseases caused by FUNGI.		03.0610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.0610
Virus Diseases
A general term for diseases caused by viruses.		03.0610